Inventor · disambiguated record
Christopher James Lord
Also filed as: LORD CHRISTOPHER · LORD CHRISTOPHER JAMES
3 granted patents·6 pending applications·1 citations·filing 2008–2023
44Inventor score
Files withTHE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL3ARTIOS PHARMA LTD1ASHWORTH ALAN1CANCER RES INST ROYAL1INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)1
Top patents by PatentIndex Score
9 records- 0158US9193689B23-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic useCANCER RES INST ROYAL·Filed 2013·Granted Nov 24, 2015·1 cites·30 claims
- 0258US2024050434A1Hormad1 therapeuticsROYAL CANCER HOSPITAL·Filed 2021·Application pending·0 cites
- 0357US2023173048A1Anti-cancer vaccines and related therapyTHE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL·Filed 2021·Application pending·0 cites
- 0451US2011212101A1Materials and methods for exploiting synthetic lethality in mismatch repair-deficient cancersMARTIN SARAH·Filed 2008·Application pending·0 cites
- 0551US2025263799A1Methods of treating cancer using replication stress modulatorsTHE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL·Filed 2023·Application pending·0 cites
- 0640US12233060B2Inhibitors of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancerTHE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL·Filed 2017·Granted Feb 25, 2025·0 cites·9 claims
- 0737US2014378525A1Materials and methods for treating pten mutated or deficient cancerASHWORTH ALAN·Filed 2012·Application pending·0 cites
- 0834US9611223B23-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic useINST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)·Filed 2014·Granted Apr 4, 2017·0 cites·33 claims
- 0932US2022387544A1Novel therapeutic useARTIOS PHARMA LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christopher James Lord files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →